share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5：募資說明書
美股SEC公告 ·  05/02 09:43

Moomoo AI 已提取核心訊息

Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $7,250,000 to $10,000,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $7,222,741 worth of common stock within the last 12 months and is now eligible to sell an additional $2,855,314. The prospectus supplement, which amends the prior prospectus dated November 29, 2023, and supplemented on March 19, 2024, specifies that the company will not sell more than one-third of the aggregate market value of its common stock held by non-affiliates in any 12-month period, which is capped at $10,078,055, as long as the public float remains below $75 million. The filing also notes the high degree of risk involved in investing in their common stock and includes a reference to the risk factors detailed in the prior prospectus supplement.
Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $7,250,000 to $10,000,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $7,222,741 worth of common stock within the last 12 months and is now eligible to sell an additional $2,855,314. The prospectus supplement, which amends the prior prospectus dated November 29, 2023, and supplemented on March 19, 2024, specifies that the company will not sell more than one-third of the aggregate market value of its common stock held by non-affiliates in any 12-month period, which is capped at $10,078,055, as long as the public float remains below $75 million. The filing also notes the high degree of risk involved in investing in their common stock and includes a reference to the risk factors detailed in the prior prospectus supplement.
Allarity Therapeutics Inc.已於2024年5月2日提交了招股說明書補充文件，將其普通股的最高總髮行價從725萬美元提高到1,000萬美元。該修正案符合與Ascendiant Capital Markets, LLC簽訂的市場發行銷售協議。在過去的12個月中，該公司已經出售了價值7,222,741美元的普通股，現在有資格再出售2855,314美元。招股說明書補充文件修訂了先前於2023年11月29日發佈的招股說明書，並於2024年3月19日進行了補充。該補充文件規定，只要公衆持有量保持在7500萬美元以下，公司在任何12個月期間出售的普通股總市值的三分之一都不會超過非關聯公司持有的普通股總市值的三分之一，上限爲10,078,055美元。該文件還指出了投資普通股所涉及的高度風險，並提到了先前的招股說明書補充文件中詳述的風險因素。
Allarity Therapeutics Inc.已於2024年5月2日提交了招股說明書補充文件，將其普通股的最高總髮行價從725萬美元提高到1,000萬美元。該修正案符合與Ascendiant Capital Markets, LLC簽訂的市場發行銷售協議。在過去的12個月中，該公司已經出售了價值7,222,741美元的普通股，現在有資格再出售2855,314美元。招股說明書補充文件修訂了先前於2023年11月29日發佈的招股說明書，並於2024年3月19日進行了補充。該補充文件規定，只要公衆持有量保持在7500萬美元以下，公司在任何12個月期間出售的普通股總市值的三分之一都不會超過非關聯公司持有的普通股總市值的三分之一，上限爲10,078,055美元。該文件還指出了投資普通股所涉及的高度風險，並提到了先前的招股說明書補充文件中詳述的風險因素。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間